Big Breaking News Could Provide Nasdaq Profile (BSGM) With Major Squeeze Potential Today
$13.00 Laidlaw & Company Price Target
BSGM trends green early and could be heating up.
Hitting an early high of $4.45 so far today, BSGM has already eclipsed its June/May high of $4.30.
Could this be the start of an even bigger move?
Also, the company dropped major news this morning. Check it out: BioSig Completes 1000 Patient Cases with its Signal Processing System for Electrophysiology
As I mentioned in my report below, BSGM could be nearing a potential squeeze as Barchart was reporting its 200-Day Simple Moving Average (SMA) was around $4.41 after this Nasdaq profile closed yesterday.
If potential resistance breaks down at the level, BSGM could start drawing serious attention as it is already trading above its 50-Day SMA and 13-Day Exponential Moving Average (EMA).
Additionally, BSGM's 5-Day EMA is trading above its 13-Day EMA in a potentially bullish trend.
Plus, with fewer than 30Mn shares in its float according to Yahoo Finance, volatility can always be in the cards on a daily basis.
Take a moment now to read my initial report and get BSGM on your radar quickly today.
*BioSig Technologies, Inc. (BSGM)*
BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals.
The Company’s first product, PURE EP(tm) System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording, and storing electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.
Here’s Why PURE EP Could Be a Game-Changer
According to XTalks, PURE EP could fill a significant need because:
“The electrograms used today can be riddled with noise and artifacts coming from other equipment found in the operating room. Such a procedure can take up to six hours, potentially yielding what is referred to in the industry as a ‘dirty signal’ that’s indiscernible to interpret by many electrophysiologists.” (1)
BioSig's PURE EP was developed to address unmet needs in a large and growing market and deliver technology to improve catheter ablation treatments for arrhythmias, Atrial Fibrillation, and Ventricular Tachycardia.
“The system is intended to acquire, digitize, amplify, filter, measure and calculate, display, record and store electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory under the supervision of licensed healthcare practitioners who are responsible for interpreting the data,” as further reported XTalks. (1)
No. 1 Potential Immediate Term Catalyst - Company's Tech To Be Featured At Stanford Retreat
BioSig’s Signal Processing Technology for Electrophysiology To Be Featured During 2021 Stanford Biodesign New Arrhythmia Technologies Retreat
Westport, CT, June 28, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company would be presenting during 2021 Stanford Biodesign New Arrhythmia Technologies Retreat, due to take place virtually on July 27, 2021. The Company will present at 2 pm PT.
Read the full article here.
No. 2 Potential Immediate Term Catalyst - Potential Squeeze On Horizon?
Check out BSGM's 6-month chart below: